Exploring the Preparation of Albendazole-Loaded Chitosan-Tripolyphosphate Nanoparticles
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Bong-Seok | - |
dc.contributor.author | Lee, Sang-Eun | - |
dc.contributor.author | Ng, Choon Lian | - |
dc.contributor.author | Kim, Jin-Ki | - |
dc.contributor.author | Park, Jeong-Sook | - |
dc.date.accessioned | 2021-06-22T20:24:58Z | - |
dc.date.available | 2021-06-22T20:24:58Z | - |
dc.date.issued | 2015-02 | - |
dc.identifier.issn | 1996-1944 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/18867 | - |
dc.description.abstract | The objective of this study was to improve the solubility of albendazole and optimize the preparation of an oral nanoparticle formulation, using beta-cyclodextrin (beta CD) and chitosan-tripolyphosphate (TPP) nanoparticles. The solubility of albendazole in buffers, surfactants, and various concentrations of acetic acid solution was investigated. To determine drug loading, the cytotoxic effects of the albendazole concentration in human hepatocellular carcinoma cells (HepG2) were investigated. The formulations were prepared by mixing the drug solution in Tween 20 with the chitosan solution. TPP solution was added dropwise with sonication to produce a nanoparticle through ionic crosslinking. Then the particle size, polydispersity index, and zeta potential of the nanoparticles were investigated to obtain an optimal composition. The solubility of albendazole was greater in pH 2 buffer, Tween 20, and beta CD depending on the concentration of acetic acid. Drug loading was determined as 100 mu g/mL based on the results of cell viability. The optimized ratio of Tween 20, chitosan/hydroxypropyl beta CD, and TPP was 2:5:1, which resulted in smaller particle size and proper zeta positive values of the zeta potential. The chitosan-TPP nanoparticles increased the drug solubility and had a small particle size with homogeneity in formulating albendazole as a potential anticancer agent. | - |
dc.format.extent | 13 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MDPI AG | - |
dc.title | Exploring the Preparation of Albendazole-Loaded Chitosan-Tripolyphosphate Nanoparticles | - |
dc.type | Article | - |
dc.publisher.location | 스위스 | - |
dc.identifier.doi | 10.3390/ma8020486 | - |
dc.identifier.scopusid | 2-s2.0-84979986544 | - |
dc.identifier.wosid | 000352052600009 | - |
dc.identifier.bibliographicCitation | MATERIALS, v.8, no.2, pp 486 - 498 | - |
dc.citation.title | MATERIALS | - |
dc.citation.volume | 8 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 486 | - |
dc.citation.endPage | 498 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Materials Science | - |
dc.relation.journalWebOfScienceCategory | Materials Science, Multidisciplinary | - |
dc.subject.keywordPlus | HYDROXYPROPYL-BETA-CYCLODEXTRIN | - |
dc.subject.keywordPlus | DRUG-DELIVERY SYSTEM | - |
dc.subject.keywordPlus | ORAL BIOAVAILABILITY | - |
dc.subject.keywordPlus | PARTICLE-SIZE | - |
dc.subject.keywordPlus | RICOBENDAZOLE | - |
dc.subject.keywordPlus | COMPLEXATION | - |
dc.subject.keywordPlus | FORMULATIONS | - |
dc.subject.keywordPlus | ABSORPTION | - |
dc.subject.keywordPlus | PARAMETERS | - |
dc.subject.keywordPlus | STABILITY | - |
dc.subject.keywordAuthor | Albendazole | - |
dc.subject.keywordAuthor | Anti-cancer effect | - |
dc.subject.keywordAuthor | Chitosan | - |
dc.subject.keywordAuthor | Nanoparticle | - |
dc.subject.keywordAuthor | Tripolyphosphate | - |
dc.identifier.url | https://www.mdpi.com/1996-1944/8/2/486 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.